Home » RESULTS—Multicenter Uveitis Steroid Treatment (MUST) Trial
RESULTS—Multicenter Uveitis Steroid Treatment (MUST) Trial
The MUST trial is a multicenter, randomized controlled clinical trial, designed to compare the fluocinolone acetonide implant to standard systemic therapy for the treatment of patients with non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
- NEI Statement—NIH study shows two treatments for uveitis equally effective, August 17, 2011
- Facts about Uveitis
- MUST Trial in ClinicalTrials.gov (NCT00132691)
Citations on the MUST Trial:
- Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Writing Committee, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2011 Aug 12. [Epub ahead of print]. PubMed
- Multicenter Uveitis Steroid Treatment Trial Research Group; Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010 Apr;149(4):550-561.e10. Epub 2010 Jan 25. PubMed
